Wellington Management Group LLP Buys New Position in ANI Pharmaceuticals, Inc. $ANIP

Wellington Management Group LLP acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 8,206 shares of the specialty pharmaceutical company's stock, valued at approximately $549,000.

Other institutional investors have also recently added to or reduced their stakes in the company. National Bank of Canada FI purchased a new position in ANI Pharmaceuticals during the first quarter worth approximately $79,000. GAMMA Investing LLC lifted its position in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares in the last quarter. Mesirow Financial Investment Management Inc. purchased a new stake in ANI Pharmaceuticals in the first quarter valued at $206,000. Rafferty Asset Management LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at $200,000. Finally, Bridgefront Capital LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at $204,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Truist Financial lifted their target price on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday, August 11th. Piper Sandler restated an "overweight" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $84.75.

Insider Activity

In other news, SVP Chad Gassert sold 20,000 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the completion of the transaction, the senior vice president directly owned 173,226 shares of the company's stock, valued at approximately $15,065,465.22. This represents a 10.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Nikhil Lalwani sold 56,960 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total value of $4,894,572.80. Following the transaction, the chief executive officer directly owned 411,219 shares of the company's stock, valued at approximately $35,336,048.67. This represents a 12.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 405,538 shares of company stock worth $35,690,131 over the last three months. Company insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Trading Up 1.1%

Shares of NASDAQ ANIP traded up $1.08 during trading on Thursday, reaching $96.00. The stock had a trading volume of 398,570 shares, compared to its average volume of 375,436. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $96.37. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The business's 50-day moving average price is $75.06 and its 200-day moving average price is $67.74. The company has a market cap of $2.08 billion, a P/E ratio of -124.67 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million during the quarter, compared to analysts' expectations of $187.18 million. During the same period in the previous year, the firm posted $1.02 EPS. ANI Pharmaceuticals's revenue for the quarter was up 53.2% on a year-over-year basis. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.